• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    2/19/25 6:00:00 AM ET
    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
    Get the next $AEMD alert in real time by email

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 2 - Today

    February 19, 2025

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Light.AI, Inc. (CBOE CA: ALGO) (FSE: 0HC)

    Keynote speaker: Hugh Cleland, Director

    9:40 – 10:10

    Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)

    Keynote speaker: Stephen Anthony Stamp, CEO, CFO & Director

    10:15 – 10:45

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    10:50 – 11:20

    22nd Century Group, Inc. (NASDAQ:XXII)

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    11:25 – 11:55

    Aethlon Medical, Inc. (NASDAQ:AEMD)

    Keynote speakers: Jim Frakes, Acting CEO and CFO & Steven LaRosa, Chief Medical Officer

    12:00 – 12:30

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    12:35 – 1:05

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Dr. David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    1:10 - 1:40

    ANGLE, plc. (OTCQX:ANPCY) (AIM: AGL)

    Keynote speakers: Andrew David William Newland, Founder, CEO & Executive Director

    1:45 - 2:15

    Touchstone Explorations, Inc. (OTC:PBEGF) (TSX:TXP) 

    Keynote speaker: Paul Raymond Baay President, CEO

    2:20 – 2:50

    Mesoblast, Ltd. (NASDAQ:MESO)

    Keynote speakers: Dr. Silviu Itescu, Founder, CEO

    2:55 – 3:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speakers: David Dodd, Chairman, President / CEO

    3:10 - 3:20

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    3:25 - 3:35

    U Power Limited (NASDAQ:UCAR) 

    Keynote speaker: Paul Li, UCAR European Representative

    3:40 – 3:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Thomas Larsen, CEO & Chairman, & Dr. William N. Pearson, Executive Vice President of Exploration

    3:55 – 4:05

    The Birch Co. (OTC:ATWT)

    Keynote speaker: Angus Martin, President & CEO

    4:10 – 4:40

    Sigyn Therapeutics, Inc. (OTCQB:SIGY)

    Keynote speaker: James Allen Joyce, CEO

    _______________________________________________________________

    Day 1

    February 18, 2025

    Companies presented yesterday:

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    B.O.S. Better Online Solutions, Ltd. (NASDAQ:BOSC)

    Keynote speaker: Eyal Cohen, President & CEO

    Brenmiller Energy, Ltd. (NASDAQ:BNRG)

    Keynote speaker: Nir Brenmiller, COO

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    U.S. Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, President, CEO & Director

    Empire Energy (ASX: EEG)

    Keynote speaker: Alex Underwood, CEO & Managing Director

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA) 

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    Highland Copper Company Inc. (OTCQB:HDRSF) (TSXV:HI)

    Keynote speaker: Barry O'Shea, CEO

    Collective Mining, Ltd. (NYSE:CNL) (TSX:CNL)

    Keynote speaker: Ari Sussman, Executive Chairman

    Ideal Power, Inc. (NASDAQ:IPWR)

    Keynote speakers: Dan Brdar, President / CEO, and Tim Burns CFO

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    Beneficient (NASDAQ:BENF)

    Keynote speaker: Brad K. Heppner, CEO

    Jaguar Health, Inc. (NASDAQ:JAGX)

    Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASPI
    $BDRX
    $BENF

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    Mesoblast Limited
    $MESO
    12/23/2024Buy → Hold
    Jefferies
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    More analyst ratings

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Smith Ryan Lewis bought $4,560 worth of shares (4,000 units at $1.14), increasing direct ownership by 0.34% to 1,183,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    9/15/25 7:00:12 AM ET
    $USEG
    Oil & Gas Production
    Energy

    Chief Operating Officer Ainscow Robert sold $71,945 worth of shares (8,438 units at $8.53), exercised 297,000 shares at a strike of $1.12 and covered exercise/tax liability with 38,861 shares, increasing direct ownership by 18% to 1,669,693 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/10/25 9:01:09 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot sold $1,371,531 worth of shares (162,153 units at $8.46), exercised 1,216,000 shares at a strike of $2.00 and covered exercise/tax liability with 285,110 shares, increasing direct ownership by 11% to 8,084,191 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/10/25 9:00:31 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

    NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York. Mesoblast Chief Executive Silviu Itescu reiterated the strong first quarter launch of Ryoncil® and product sales in the treatment of children with steroid-refractory acute graft versus host

    9/14/25 9:18:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective September 5th, 2025, to two non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 87,500 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an ind

    9/10/25 5:30:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio upgraded by UBS with a new price target

    UBS upgraded Gossamer Bio from Neutral to Buy and set a new price target of $9.00

    9/10/25 7:56:26 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast downgraded by Jefferies

    Jefferies downgraded Mesoblast from Buy to Hold

    7/18/25 8:10:38 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Gossamer Bio with a new price target

    Scotiabank initiated coverage of Gossamer Bio with a rating of Sector Outperform and set a new price target of $11.00

    7/14/25 8:51:47 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    SEC Filings

    View All

    SEC Form 424B5 filed by B.O.S. Better Online Solutions

    424B5 - BOS BETTER ONLINE SOLUTIONS LTD (0001005516) (Filer)

    9/15/25 5:07:27 PM ET
    $BOSC
    Computer Communications Equipment
    Telecommunications

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/15/25 12:14:25 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    9/15/25 7:48:07 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Smith Ryan Lewis bought $4,560 worth of shares (4,000 units at $1.14), increasing direct ownership by 0.34% to 1,183,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    9/15/25 7:00:12 AM ET
    $USEG
    Oil & Gas Production
    Energy

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Smith Ryan Lewis bought $2,340 worth of shares (2,000 units at $1.17), increasing direct ownership by 0.17% to 1,179,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    8/14/25 7:00:13 AM ET
    $USEG
    Oil & Gas Production
    Energy

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Leadership Updates

    Live Leadership Updates

    View All

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    BOS Continues Strong Growth Trajectory in Q2 2025, Sales Increase 36% Year-Over-Year

    RISHON LE ZION, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. ("BOS" or the "Company") (NASDAQ:BOSC) reported financial results for the second quarter and first half ended June 30, 2025, continuing its growth trajectory. Second Quarter 2025 Financial Highlights Revenue increased 36.4% to $11.5 million, compared to $8.5 million in Q2 2024.Net income increased 52.7% to $765,000, or $0.13 per basic share, compared to $501,000, or $0.09 per basic share, in Q2 2024.EBITDA increased to $898,000 compared to $817,000 in Q2 2024.Contracted Backlog was $24 million as of June 30, 2025, compared to $22 million on March 31, 2025, and $27 million on December 31, 2024.Cash

    8/21/25 7:30:00 AM ET
    $BOSC
    Computer Communications Equipment
    Telecommunications

    Ideal Power Reports Second Quarter 2025 Financial Results

    AUSTIN, Texas, Aug. 14, 2025 /PRNewswire/ -- Ideal Power Inc. (NASDAQ:IPWR) ("Ideal Power," the "Company," "we," "us" or "our"), developer and innovative provider of the highly efficient and broadly patented B-TRAN® bidirectional semiconductor power switch, reports results for its second quarter ended June 30, 2025. "Our first design win customer is nearing completion of their B-TRAN®-enabled solid-state circuit breaker (SSCB) prototype testing. Following their initial product rollout later this year, we anticipate this OEM will expand its offerings to include a suite of B-TRAN®-enabled SSCBs with a wide range of power ratings, presenting us with a significant revenue growth opportunity. Fur

    8/14/25 9:20:00 AM ET
    $IPWR
    Semiconductors
    Technology

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care